Site icon Scientific Inquirer

A Fat-Storage Gene Active Outside the Brain May Raise the Risk of Anorexia

Glowing DNA double helix with molecular structures in a laboratory

A glowing DNA helix and molecular structures bring genetics research to life in a laboratory setting.

Anorexia nervosa has one of the highest death rates of any psychiatric illness. Genetics is known to play a part in who develops it, but the biological routes from gene to illness have been hard to pin down, and most of the search has concentrated on the brain. A study supported by Michigan State University points somewhere else: to a gene that is active mainly in fat and muscle.

The gene is called PLIN4, and it helps control how cells store fat. In a paper published in Frontiers in Psychiatry, researchers report that patients with anorexia were almost four times as likely as a healthy reference population to carry rare variants of the gene that are predicted to be damaging. The result suggests that, in some patients, a disruption in how the body stores and uses energy may contribute to the illness.

“The idea of an anorexic gene not in the brain is completely novel,” said Michael Lutter, a physician who treats patients with eating disorders and who has spent years searching for genes linked to the condition.

Seventeen Patients in 154

Lutter, formerly of the University of Iowa, collaborated on the work with A.J. Robison of Michigan State. The researchers sequenced the protein-coding portions of the genome in 154 patients. This was not a random sample of people with anorexia. The patients were chosen because they had a strong family history of the illness, had failed to respond to multiple treatments or showed unusual clinical features.

Seventeen of them, about 11 percent, carried rare variants predicted to damage PLIN4. In the healthy reference population the figure was about 3 percent. Six patients had variants severe enough that they would probably disable the gene altogether. In four of those six families, a close relative who also had an eating disorder carried the same change.

That family pattern is suggestive, but the authors are explicit about the study’s main weakness. Because the sample was so specialized, the finding needs to be replicated in a larger, independent group of patients before anyone can say how broadly it applies.

Beyond a Purely Psychiatric View

For Robison, part of the significance lies in what the result says about how the disorder is perceived. Anorexia is often regarded as purely psychiatric, he said, or dismissed as a matter of vanity. He suggested that the vanity explanation may partly reflect bias against women, who are affected about ten times as often as men. A risk gene that operates in body tissue, not the brain, challenges the assumption that the relevant biology is all in the head.

The illness clearly runs in families. Twin studies, including the Michigan Twins Project, show that having a first-degree relative with anorexia raises a person’s risk to five to ten times that of the general population. Yet most of the genetic variants responsible remain unidentified.

Lutter compares his search to the discovery of BRCA1 and BRCA2, the rare variants that sharply raise the risk of breast and ovarian cancer. The comparison has limits, which he acknowledges. Anorexia is polygenic, meaning that many variants each contribute a share of the risk, and no single gene is likely to explain most cases.

Understudied and Underfunded

The value of finding such genes, the researchers argue, is in the pathways they reveal. Genes work within larger networks, with regulators upstream and functions downstream, and identifying one member can expose the rest, including possible targets for drugs. Robison cautioned that identifying genes will not cure the disease. It can show what is driving the illness in many people and so guide the development of treatments.

New treatments are badly needed. Care for anorexia has changed little beyond nutritional rehabilitation and psychotherapy, and no drug approved by the U.S. Food and Drug Administration targets the condition specifically. Research money has been scarce as well. An analysis of National Institutes of Health funding from 2011 to 2023 placed eating disorders among the two lowest-funded categories.

The team’s next steps are to look for other genetic differences that affect fat storage and susceptibility, and to examine patients’ body fat directly for abnormalities. Lutter’s stated aim is for people with anorexia to have better treatment options and better outcomes than they do now.


Endnotes

  1. “Increased frequency of rare damaging variants in PLIN4 in patients with anorexia nervosa.” (October 8, 2026). Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2026.1937613
  2. Michigan State University (October 8, 2026). “Anorexia risk may begin outside the brain, new study suggests.” EurekAlert! https://www.eurekalert.org/news-releases/1146539
Exit mobile version